A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study

Creative Commons License

YALÇIN Ş., Yildiz R., DANE F., Karaoglu A., OKSUZOGLU B., Ozyilkan O., ...Daha Fazla

ONCOTARGETS AND THERAPY, cilt.11, ss.1223-1228, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 11
  • Basım Tarihi: 2018
  • Doi Numarası: 10.2147/ott.s148917
  • Sayfa Sayıları: ss.1223-1228


Introduction: The introduction of targeted therapies in renal cell carcinoma has significantly improved its prognosis and treatment outcomes in recent years. Such treatment options are targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mammalian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and mammalian target of the rapamycin inhibitors, overall survival has increased up to 2 years. In Turkey, due to applicable reimbursement conditions for patients with metastatic renal cell carcinoma (mRCC), interferon use is mandated as a first-line treatment, thus providing information on the use of everolimus only after initial interferon and second-line VEGF-targeted treatments such as VEGF-TKI.